Nu Skin Enterprises, Inc. (NUS) Key Metrics
NUS valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $250.2M
- Enterprise value
- $296.8M
- P/E (TTM)
- — 10-yr median 18.7
- Forward P/E
- 4.0
- PEG ratio
- 0.78
- Price / sales
- 0.2 10-yr median 1.0
- Price / book
- 0.4 10-yr median 2.7
- EV / EBITDA
- 7.5 10-yr median 8.9
- Dividend yield
- 4.67% $0.24 a year
- Beta
- 0.90
NUS key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsNUS valuation Price multiples at each fiscal year-end price.
NUS returns How much profit the business earns on the capital it uses.
NUS per-share figures Results divided by the shares outstanding at year-end.
NUS financial health Debt, liquidity and how easily interest is covered.
NUS efficiency & capital use Working capital cycle and where the cash goes.
NUS valuation history
NUS returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
NUS debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
NUS cash returned to shareholders
NUS price vs earnings per share
NUS key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $483.9M | $342.2M | $968.3M | $2.13B | $2.61B | $2.88B | $2.29B | $3.46B | $3.74B | $2.68B |
| Enterprise value | $608.3M | $622.4M | $1.31B | $2.37B | $2.76B | $2.96B | $2.45B | $3.50B | $3.69B | $2.73B |
| P/E ratio | 3.0 | — | 112.7 | 20.3 | 17.7 | 15.1 | 13.2 | 28.4 | 28.9 | 18.7 |
| Price / sales | 0.3 | 0.2 | 0.5 | 1.0 | 1.0 | 1.1 | 0.9 | 1.3 | 1.6 | 1.2 |
| Price / book | 0.6 | 0.5 | 1.2 | 2.4 | 2.9 | 3.2 | 2.6 | 4.4 | 5.3 | 4.0 |
| Price / free cash flow | 10.5 | 4.9 | 16.1 | 43.5 | 35.8 | 9.1 | 20.5 | 26.2 | 15.4 | 11.9 |
| Price / operating cash flow | 6.0 | 3.1 | 8.2 | 19.7 | 18.4 | 7.6 | 12.9 | 17.1 | 12.4 | 9.7 |
| EV / sales | 0.4 | 0.4 | 0.7 | 1.1 | 1.0 | 1.1 | 1.0 | 1.3 | 1.6 | 1.2 |
| EV / EBITDA | 2.3 | — | 6.4 | 13.6 | 8.6 | 8.9 | 7.1 | 11.6 | 10.7 | 9.0 |
| EV / free cash flow | 13.2 | 8.9 | 21.7 | 48.4 | 37.8 | 9.4 | 21.9 | 26.4 | 15.2 | 12.1 |
| Earnings yield | 33.1% | −42.8% | 0.9% | 4.9% | 5.6% | 6.6% | 7.6% | 3.5% | 3.5% | 5.3% |
| Free cash flow yield | 9.5% | 20.5% | 6.2% | 2.3% | 2.8% | 10.9% | 4.9% | 3.8% | 6.5% | 8.4% |
| Dividend yield | 2.4% | 3.5% | 8.0% | 3.6% | 2.9% | 2.7% | 3.6% | 2.3% | 2.0% | 2.9% |
| Shareholder yield (dividends + buybacks) | 6.6% | 4.1% | 9.4% | 6.9% | 6.0% | 7.7% | 3.6% | 4.3% | 3.9% | 12.1% |
| Share price at fiscal year-end | $9.62 | $6.89 | $19.42 | $42.16 | $50.75 | $54.63 | $40.98 | $61.33 | $68.23 | $47.78 |
| Per share | ||||||||||
| Revenue per share | $29.53 | $34.88 | $39.49 | $44.05 | $52.42 | $48.93 | $43.28 | $47.44 | $41.55 | $39.36 |
| Earnings per share | $3.18 | −$2.95 | $0.17 | $2.07 | $2.86 | $3.63 | $3.10 | $2.16 | $2.36 | $2.55 |
| Operating cash flow per share | $1.60 | $2.25 | $2.38 | $2.14 | $2.75 | $7.19 | $3.18 | $3.59 | $5.52 | $4.91 |
| Free cash flow per share | $0.91 | $1.41 | $1.21 | $0.97 | $1.42 | $5.98 | $2.00 | $2.34 | $4.42 | $4.01 |
| Cash per share | $4.77 | $3.99 | $5.37 | $5.51 | $6.90 | $8.03 | $6.15 | $7.05 | $7.99 | $6.56 |
| Book value per share | $16.01 | $13.12 | $16.49 | $17.76 | $17.75 | $16.95 | $15.65 | $13.84 | $12.85 | $11.84 |
| Tangible book value per share | $13.50 | $9.94 | $9.75 | $12.35 | $12.24 | $11.40 | $10.70 | $8.77 | $9.52 | $8.66 |
| Dividends per share | $0.24 | $0.24 | $1.56 | $1.52 | $1.48 | $1.49 | $1.47 | $1.43 | $1.39 | $1.40 |
| Capex per share | $0.68 | $0.84 | $1.17 | $1.17 | $1.33 | $1.21 | $1.18 | $1.25 | $1.10 | $0.90 |
| Debt per share | $7.24 | $9.63 | $12.18 | $10.30 | $9.80 | $9.48 | $9.07 | $7.62 | $7.09 | $7.43 |
| Shares outstanding | 50.3M | 49.7M | 49.9M | 50.5M | 51.4M | 52.8M | 55.9M | 56.5M | 54.9M | 56.1M |
| Change in shares outstanding | +1.3% | −0.4% | −1.3% | −1.8% | −2.5% | −5.7% | −1.0% | +3.0% | −2.2% | −5.0% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 22.0% | −19.9% | 1.0% | 11.6% | 16.3% | 21.6% | 20.9% | 16.4% | 18.9% | 19.2% |
| Return on invested capital (ROIC) | 8.0% | −11.4% | 2.1% | 10.1% | 14.6% | 19.1% | 19.6% | 18.2% | 20.1% | 20.9% |
| Return on assets (ROA) | 11.1% | −9.0% | 0.5% | 5.6% | 7.6% | 10.3% | 10.0% | 7.4% | 8.4% | 9.6% |
| Return on tangible assets | 12.5% | −11.2% | 0.6% | 6.8% | 9.1% | 11.5% | 11.6% | 8.7% | 9.2% | 11.0% |
| Free cash flow margin | 3.1% | 4.1% | 3.1% | 2.2% | 2.7% | 12.2% | 4.6% | 4.9% | 10.6% | 10.2% |
| Income quality (OCF / net income) | 0.50 | — | 13.80 | 1.03 | 0.96 | 1.98 | 1.03 | 1.66 | 2.34 | 1.92 |
| Financial health | ||||||||||
| Total debt | $364.3M | $478.2M | $607.3M | $520.5M | $503.8M | $500.4M | $507.0M | $430.5M | $388.6M | $416.9M |
| Cash & short-term investments | $239.8M | $198.0M | $267.8M | $278.5M | $354.8M | $423.9M | $344.0M | $398.3M | $438.2M | $368.1M |
| Net debt | $124.4M | $280.2M | $339.5M | $242.0M | $149.0M | $76.5M | $163.0M | $32.2M | −$49.6M | $48.8M |
| Debt / equity | 0.45 | 0.73 | 0.74 | 0.58 | 0.55 | 0.56 | 0.58 | 0.55 | 0.55 | 0.63 |
| Debt / assets | 0.26 | 0.33 | 0.34 | 0.29 | 0.26 | 0.26 | 0.29 | 0.25 | 0.24 | 0.28 |
| Net debt / EBITDA | 0.47 | — | 1.66 | 1.38 | 0.47 | 0.23 | 0.47 | 0.11 | −0.14 | 0.16 |
| Current ratio | 2.08 | 1.82 | 2.13 | 2.12 | 1.65 | 1.66 | 2.07 | 1.82 | 1.74 | 1.79 |
| Quick ratio | 1.40 | 1.17 | 1.28 | 1.15 | 0.89 | 1.08 | 1.30 | 1.15 | 1.17 | 1.16 |
| Interest coverage | 6.5 | -5.7 | 1.9 | 5.1 | 21.3 | 19.7 | 13.9 | — | — | — |
| Working capital | $284.0M | $242.0M | $373.0M | $400.6M | $343.3M | $360.3M | $383.4M | $359.6M | $330.4M | $315.3M |
| Invested capital | $929.7M | $931.7M | $1.16B | $1.14B | $1.06B | $970.7M | $1.04B | $814.1M | $655.0M | $712.8M |
| Tangible asset value | $679.0M | $493.6M | $485.9M | $624.2M | $629.3M | $601.8M | $598.4M | $495.3M | $522.0M | $485.6M |
| Net current asset value | −$52.4M | −$278.9M | −$282.6M | −$163.8M | −$120.8M | −$159.6M | −$153.6M | −$113.3M | −$107.5M | −$95.6M |
| Graham number | $33.87 | — | $8.00 | $28.79 | $33.82 | $37.19 | $33.06 | $25.93 | $26.12 | $26.06 |
| Graham net-net per share | −$4.80 | −$9.79 | −$10.47 | −$8.64 | −$7.93 | −$8.23 | −$6.69 | −$5.78 | −$5.39 | −$5.23 |
| Capital allocation | ||||||||||
| Dividends paid | $11.8M | $11.9M | $77.6M | $77.0M | $76.3M | $78.4M | $82.2M | $80.6M | $76.1M | $78.4M |
| Share buybacks (net) | $20.0M | $2.1M | $13.0M | $70.0M | $80.4M | $144.3M | $825,000 | $69.6M | $71.7M | $247.2M |
| Dividend payout ratio | 7.4% | — | 903.1% | 73.5% | 51.8% | 41.0% | 47.4% | 66.1% | 58.8% | 54.8% |
| Dividends + buybacks / free cash flow | 69.3% | 19.9% | 150.7% | 300.1% | 214.7% | 70.6% | 74.2% | 113.4% | 61.0% | 144.7% |
| Capex / revenue | 2.3% | 2.4% | 3.0% | 2.7% | 2.5% | 2.5% | 2.7% | 2.6% | 2.6% | 2.3% |
| Capex / operating cash flow | 42.7% | 37.2% | 49.3% | 54.7% | 48.5% | 16.8% | 37.1% | 34.7% | 19.9% | 18.2% |
| Capex / depreciation | 0.66 | 0.60 | 0.82 | 0.81 | 0.90 | 0.86 | 0.86 | 0.85 | 0.84 | 0.69 |
| Stock-based compensation / revenue | 1.6% | 0.9% | 0.8% | 0.6% | 0.9% | 0.9% | 0.4% | 1.0% | 0.8% | 0.4% |
| R&D / revenue | — | 0.8% | 1.1% | 1.0% | 1.0% | 0.9% | 1.2% | 0.9% | 1.0% | 1.1% |
| SG&A / revenue | 63.3% | 65.3% | 65.5% | 64.5% | 64.3% | 64.5% | 64.9% | 64.7% | 65.9% | 66.9% |
| Efficiency | ||||||||||
| Days sales outstanding | 11.1 | 13.0 | 11.1 | 7.3 | 7.1 | 8.0 | 7.8 | 5.9 | 5.2 | 5.5 |
| Days of inventory on hand | 148.4 | 156.0 | 186.8 | 215.8 | 193.1 | 163.7 | 179.5 | 158.1 | 183.0 | 187.9 |
| Days payables outstanding | 24.6 | 25.9 | 29.0 | 30.1 | 31.4 | 29.2 | 27.2 | 28.2 | 33.3 | 25.6 |
| Cash conversion cycle (days) | 134.9 | 143.1 | 169.0 | 193.0 | 168.7 | 142.6 | 160.1 | 135.8 | 154.8 | 167.8 |
| Receivables turnover | 32.88 | 28.01 | 32.75 | 50.21 | 51.51 | 45.40 | 46.70 | 61.96 | 70.78 | 66.24 |
| Payables turnover | 14.86 | 14.11 | 12.61 | 12.14 | 11.63 | 12.52 | 13.43 | 12.95 | 10.96 | 14.28 |
| Inventory turnover | 2.46 | 2.34 | 1.95 | 1.69 | 1.89 | 2.23 | 2.03 | 2.31 | 1.99 | 1.94 |
| Asset turnover | 1.03 | 1.06 | 1.09 | 1.19 | 1.40 | 1.39 | 1.40 | 1.63 | 1.49 | 1.48 |
| Average receivables | $45.2M | $61.8M | $60.1M | $44.3M | $52.3M | $56.9M | $51.8M | $43.2M | $32.2M | $33.3M |
| Average payables | $30.5M | $39.0M | $48.5M | $52.0M | $58.1M | $52.6M | $43.3M | $49.0M | $45.8M | $35.0M |
| Average inventory | $184.4M | $235.1M | $313.1M | $373.1M | $357.1M | $295.1M | $285.9M | $274.6M | $251.7M | $257.6M |
| Intangibles / total assets | 9.0% | 10.7% | 18.6% | 15.0% | 14.9% | 14.9% | 15.7% | 16.9% | 11.5% | 12.1% |
Computed from NUS's annual financial statements (latest annual report filed February 13, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
NUS valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Nu Skin Enterprises traded at 3.0 times earnings, against a 10-year median of 18.7. Nu Skin Enterprises earned a return on equity of 22.0% and a return on invested capital of 8.0% in fiscal 2025. It ended the year with $364.3 million of debt and $239.8 million in cash and short-term investments, net debt of $124.4 million. It returned $31.9 million to shareholders: $11.8 million in dividends and $20.0 million in share buybacks, 69% of free cash flow. The share count fell 10.3% from 56.1M to 50.3M over 9 years.
See the NUS income statement, the NUS chart for price history, or the NUS stock overview for the latest quote and news.
NUS key metrics FAQ
What is Nu Skin Enterprises's P/E ratio?
Nu Skin Enterprises traded at 3.0 times earnings at the end of fiscal 2025.
What is Nu Skin Enterprises's EV/EBITDA?
Nu Skin Enterprises's enterprise value was 2.3 times EBITDA at the end of fiscal 2025 (enterprise value $608.3 million, EBITDA $262.4 million); the current EV/EBITDA is 7.5.
What is Nu Skin Enterprises's return on equity?
Nu Skin Enterprises's return on equity (ROE) was 22.0% in fiscal 2025: net income of $160.2 million on average shareholders' equity of $728.3 million.
What is Nu Skin Enterprises's ROIC?
Nu Skin Enterprises's return on invested capital was 8.0% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Nu Skin Enterprises have?
Nu Skin Enterprises had total debt of $364.3 million at the end of fiscal 2025, a debt-to-equity ratio of 0.45 and $124.4 million of net debt (0.47 times EBITDA).
What is Nu Skin Enterprises's dividend yield?
Nu Skin Enterprises's forward dividend yield is 4.67%. Nu Skin Enterprises paid $11.8 million in dividends in fiscal 2025 ($0.24 per share), a payout ratio of 7.4%.
Does Nu Skin Enterprises buy back its shares?
Yes. Nu Skin Enterprises spent $20.0 million on net share repurchases in fiscal 2025 Shares outstanding changed +1.3% over the year, to 50.3M..
What is Nu Skin Enterprises's free cash flow yield?
Nu Skin Enterprises generated $46.0 million of free cash flow in fiscal 2025, a free cash flow yield of 9.5% on its market value at year-end ($483.9 million).
What is Nu Skin Enterprises's current ratio?
Nu Skin Enterprises's current ratio was 2.08 at the end of fiscal 2025: current assets were 2.08 times current liabilities.